Clinical trials: Stage 1 Hypertension
Essential Hypertension
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2…
- Trial name
- Benibest (NCT00890591)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Volunteers
- 144 people
- Sponsor
- Daiichi Sankyo
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Healthy Adult Participants
Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.
- Trial name
- NCT06429930
- Testing
- L608 Liposomal inhalation suspension
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure.
- Trial name
- NCT00403481
- Testing
- olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
- Where
- 27 sites in United States
- Volunteers
- 192 people
- Sponsor
- Daiichi Sankyo
High Blood Pressure
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
This is an open-label, not controlled, sequential, dose escalation study of 16 weeks' duration. The study is composed of two periods: a 0-2 week optional wash-out period depending on previous antihypertensive treatment(s)…
- Trial name
- ANDROMEDA (NCT01056731)
- Testing
- Aliskiren and HCTZ
- Where
- 7 sites in Venezuela
- Volunteers
- 253 people
- Sponsor
- Novartis
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
An open-label study to characterize the effects of mild, moderate, and severe Hepatic Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in comparison with healthy volunteers with normal…
- Trial name
- NCT04200573
- Testing
- Ampreloxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Osteoarthritis, Hypertension
A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure
To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
- Trial name
- HCT3012-X-111 (NCT00662610)
- Testing
- naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
- Where
- 29 sites in United States
- Volunteers
- 120 people
- Sponsor
- NicOx
Stage 1 Hypertension
Bioactive Milk Peptides and Blood Pressure
The purpose of this study is to investigate the effects of bioactive milk peptides on blood pressure in mildly hypertensive subjects.
- Trial name
- NCT01031485
- Testing
- Milk peptides and plant sterols
- Where
- Finland
- Sponsor
- Valio Ltd
Hypertension
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
Essential hypertension is a widespread disease which affects one out of every three adults in the industrialized world. It contributes to cardiovascular disease development, a major and well established risk factor.
- Trial name
- NCT00351130
- Testing
- valsartan, amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis
Open-angle Glaucoma
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.
- Trial name
- NCT03488550
- Testing
- ANX007
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Annexon, Inc.
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
This is a Phase 1B, randomized, participant- and investigator-blinded, placebo-controlled, multi-center clinical trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in…
- Trial name
- PAH (NCT03926793)
- Testing
- GB002, Generic Dry Powder Inhaler
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Hypertension
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
- Trial name
- NCT00422461
- Testing
- PF-00489791
- Where
- 20 sites in United States
- Volunteers
- 135 people
- Sponsor
- Pfizer
Hypertension
Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.
- Trial name
- NCT01415505
- Testing
- Nebivolol, Valsartan and Hydrochlorothiazide
- Where
- 135 sites in United States
- Volunteers
- 812 people
- Sponsor
- Forest Laboratories
Pulmonary Hypertension
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models.
- Trial name
- NCT02587325
- Testing
- nab-sirolimus
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
This 14 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients 65 years of age or older with high blood pressure.
- Trial name
- NCT00412932
- Testing
- Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
- Where
- 29 sites in United States
- Volunteers
- 178 people
- Sponsor
- Daiichi Sankyo
Uncontrolled Stage 2 Hypertension
REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /
This is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System in subjects with uncontrolled stage 2 hypertension in order to assess the safety and effectiveness…
- Trial name
- REDUCED (NCT05372679)
- Testing
- Renal denervation
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- SoniVie Inc.
Pulmonary Arterial Hypertension
Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
The AIR001-CS05 study evaluated the safety and efficacy (effectiveness) of AIR001 over 16 weeks in subjects who have PAH. The purpose of the AIR001-CS06 study is to evaluate the intermediate / long-term safety of AIR001 in…
- Trial name
- NCT01725269
- Testing
- AIR001
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 17 people
- Sponsor
- Aires Pharmaceuticals, Inc.
Hypertension
Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)
The purpose of this study is to determine the efficiency of Olmesartan medoxomile (OLMETEC®) alone or in combination with hydrochlorothiazide (OLMETEC PLUS®) in the reduction of arterial blood pressure in patients with light to…
- Trial name
- NCT00811226
- Testing
- olmesartan medoxomile alone or combined with hydrochlorothiazide,
- Volunteers
- 450 people
- Sponsor
- Schering-Plough
Primary Open-angle Glaucoma, Ocular Hypertension
Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
This Phase 1/2a study is intended to assess the safety, tolerability, and effects on intraocular pressure of two dose levels and two dose frequencies of LX7101 when administered topically in the eyes of patients diagnosed with…
- Trial name
- NCT01528111
- Testing
- LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- Lexicon Pharmaceuticals